ALPN(Delisted)
Alpine Immune·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALPN
Alpine Immune Sciences, Inc.
A clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases
188 East Blaine Street, Suite 200, Seattle, WA 98102
--
Alpine Immune Sciences, Inc., formerly known as N30 Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on December 30, 2014. The company is a clinical-stage pharmaceutical company dedicated to the discovery and development of innovative, protein-based immunotherapies for the treatment of autoimmune and inflammatory diseases. The company's approach includes a proprietary scientific platform that translates innate immune system proteins into differentiated, multi-target therapies. The company is seeking to create best-in-class or best-in-class multifunctional immunotherapies through unique protein engineering technologies to improve outcomes for patients with serious diseases.
Company Financials
EPS
ALPN has released its 2024 Q1 earnings. EPS was reported at -0.28, versus the expected -0.41, beating expectations. The chart below visualizes how ALPN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ALPN has released its 2024 Q1 earnings report, with revenue of 7.03M, reflecting a YoY change of -25.09%, and net profit of -17.92M, showing a YoY change of -35.07%. The Sankey diagram below clearly presents ALPN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
